Marex Group’s Fractyl Health GUTS Stock Holding History

Marex Group’s Portfolio GUTS Stock Details GUTS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$13.5K	Buy	+29,537	New	+$27.2K	﹤0.01%	990

Other funds holding GUTS

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Pale Fire Capital SE Prague, Czech Republic $1.14B AUM 42.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marex Group's GUTS Position: Q1 2026 in Review

Marex Group opened a new position in Fractyl Health (GUTS) in Q1 2026: 29,537 shares worth $13.5K. The stake represents ﹤0.01% of the portfolio and ranks #990 among its holdings.

83 funds tracked by Wall St. Rank hold GUTS as of Q1 2026.

Marex Group held 29,537 shares of Fractyl Health worth $13.5K as of Q1 2026.
Fractyl Health was a new Marex Group position in Q1 2026.
Fractyl Health made up ﹤0.01% of Marex Group's portfolio in Q1 2026, its #990 holding.
83 funds tracked by Wall St. Rank held Fractyl Health as of Q1 2026.

Based on Marex Group's 13F filing for Q1 2026, filed 13 May 2026.